RWS buys US life sciences translation company

Corporate Translations Inc (CTi), the life sciences translation and linguistic validation provider, has been acquired by RWS, the UK-based provider of intellectual property support services. The acquisition is in line with the strategy of complementing organic growth with selective acquisition.
CTi is based in Connecticut, US, and founded in 1990 to cater for the growing demand for high quality translation services in the life sciences sector. It is now a recognised leader in successfully managing complex translation projects on behalf of the world’s top pharmaceutical and biotech companies and their Clinical Research Organisation partners. As CTi’s customers operate in highly regulated and audited industries, they place a premium on high quality translations being delivered to specific deadlines. CTi enjoys a preferred supplier relationship with many of its customers, with extraordinary penetration of the blue chip life science community.
RWS already focuses on the life sciences sector, through its patent translation and filing solutions, and with its separate Medical Translation Division which includes the linguistic validation specialist PharmaQuest.
The scale of CTi, combined with the specialist RWS divisions will immediately transform the Group to a preeminent position in life sciences translations and linguistic validation and further enhance its competitive standing amongst the largest specialist translation companies in the world.
Andrew Brode, Chairman of RWS Holdings, commented: “We are delighted to have acquired CTi, which greatly expands our exposure to the attractive and growing life sciences sector through a world leading language services provider in this field. With its focus on supporting clients in the delivery of their intellectual property pipelines, CTi is an excellent fit with RWS’ leading position in IP service provision.”